Catalyst
Slingshot members are tracking this event:
Celldex Therapeutics (CLDX) Presents Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CLDX |
|
|
||||
Additional Information
- Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief -
- Median duration of response 77+ days in Cold Urticaria and 57+ days in Symptomatic Dermographism -
- Serum tryptase and skin mast cell depletion mirror clinical activity -
- Favorable safety profile -
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 09, 2021
Related Projects
- Discussing Celldex’ CDX-0159 in Chronic Inducible Urticaria, following Phase 1b Results CLDX Executed On: Jul 16, 2021 at 11:00 AM EDT
- A Second View: Discussing the potential of Celldex’ CDX-0159 vs Xolair in Chronic Urticaria CLDX, NVS, ALLK Executed On: May 18, 2021 at 01:00 PM EDT
Related Keywords
Cdx-0159, Chronic Inducible Urticaria
